Venus-Vitae Pivotal Study Smart-Align Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.

Also called NCT05991271

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Venus MedTech (HangZhou) Inc. (from the registry)
Registry
  • NCT NCT05991271
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT05991271. Allocation not applicable; no masking; primary purpose treatment. Start 2023-10-31 (anticipated); primary completion 2024-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Venus-Vitae Pivotal Study Smart-Align Study
Condition
Aortic Valve Stenosis
Intervention (Device)
Venus-Vitae Transcatheter Heart Valve System
Lead sponsor
Venus MedTech (HangZhou) Inc. (class: industry)

Record details

Record id
cardio:ct-nct05991271
Content hash
67d9e02d66cdb39c35e8bf4205f7fc04c27baadea5c2900f310ee1e141830e1f